Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Life Sciences Tools & Services
NASDAQ | Common Stock
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide.
It operates in two segments, Clinical Research and Data Solutions.
The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis.
The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market.
Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data.
PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases.
The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014.
PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
As of July 1, 2021, PRA Health Sciences, Inc. operates as a subsidiary of ICON Public Limited Company.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Apr 28, 21 | 1.35 Increased by +28.57% | 1.33 Increased by +1.54% |
| Feb 24, 21 | 1.55 Increased by +0.65% | 1.46 Increased by +6.46% |
| Nov 4, 20 | 1.30 Decreased by -1.52% | 1.14 Increased by +14.07% |
| Aug 6, 20 | 0.86 Decreased by -29.51% | 0.82 Increased by +4.50% |
| Apr 30, 20 | 1.05 Decreased by -4.55% | 1.00 Increased by +5.34% |
| Feb 20, 20 | 1.54 Increased by +17.56% | 1.47 Increased by +4.63% |
| Oct 30, 19 | 1.32 Increased by +16.81% | 1.29 Increased by +2.31% |
| Jul 31, 19 | 1.22 Increased by +22.00% | 1.17 Increased by +4.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 21 | 933.77 M Increased by +19.15% | 56.94 M Increased by +40.04% | Increased by +6.10% Increased by +17.53% |
| Dec 31, 20 | 873.46 M Increased by +9.15% | 51.26 M Decreased by -31.48% | Increased by +5.87% Decreased by -37.22% |
| Sep 30, 20 | 796.31 M Increased by +2.00% | 91.25 M Increased by +9.93% | Increased by +11.46% Increased by +7.78% |
| Jun 30, 20 | 729.89 M Decreased by -4.38% | 13.87 M Decreased by -66.27% | Increased by +1.90% Decreased by -64.72% |
| Mar 31, 20 | 783.71 M Increased by +8.54% | 40.66 M Decreased by -7.77% | Increased by +5.19% Decreased by -15.03% |
| Dec 31, 19 | 800.24 M Increased by +9.67% | 74.80 M Increased by +4.69% | Increased by +9.35% Decreased by -4.55% |
| Sep 30, 19 | 780.69 M Increased by +8.79% | 83.01 M Increased by +5.45 K% | Increased by +10.63% Increased by +5.00 K% |
| Jun 30, 19 | 763.31 M Increased by +5.60% | 41.13 M Decreased by -2.02% | Increased by +5.39% Decreased by -7.22% |